Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

An Accurate, Non-invasive, and Cost-effective Methylome Test for Early Cancer Detection

Award Number: R43CA246941
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2021

Group Awards By:

View Award Description

An Accurate, Non-invasive, and Cost-effective Methylome Test for Early Cancer Detection - The long-term goal of this project is to develop and market a commercially viable, blood-based methylation profiling test that can detect and locate cancer early. Clinical intervention in the early stages of cancer can greatly improve the survival of cancer patients. Despite the tremendous demand for early detection methods in the clinical practice, few technologies exist on the market. To address this unmet need, with support from the NIH, our partner’s team at UCLA has developed an approach based on the genome-wide methylation analysis of cell-free DNA (cfDNA). Their novel technology, called CancerDetector, not only detects cancer early but also infers its location (tissue of origin). To increase the power of this computational framework, the same UCLA team together with EarlyDx team recently developed a novel experimental approach, called cell-free DNA Reduced Representation Bisulfite Sequencing (cfRRBS), that efficiently enriches the cfDNA fragments covering methylation sites in a blood sample. Combining the two innovations yields a test with high sensitivity and specificity in early-stage liver cancer patients. This test is now ready to be adapted for clinical use. The proposed project will translate these proof-of-principle laboratory protocols into a commercial-grade assay, and validate its effectiveness for the detection of liver cancer. This project is for a Phase I feasibility study. Our specific aims are as follows: Aim 1) Develop a commercial prototype of the EarlyDx4MethylScan assay for accurate and cost4effective genome4wide methylation profiling; Aim 2) Validate the EarlyDx4MethylScan assay for the detection of liver cancer. Engineered samples of fragmented DNAs will be used in Aim 1 to ensure the reproducibility of the assay during development. The CancerDetector algorithm has already been implemented in our cloud-computing platform. Using this platform, the new assay will be used to perform cancer prediction in a cohort of 100 real liver cancer patients and 100 controls. Phase I will be completed by successfully demonstrating the feasibility of liver cancer early detection. Phase II (and beyond) will further apply the test to multiple types of cancer, and eventually commercialize the test: first as a research product for labs, and finally as a clinical product ready for hospitals.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	EARLYDIAGNOSTICS INC	570 WESTWOOD PLZ STE 6350	LOS ANGELES	CA	90095	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	1	2/1/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	EARLYDIAGNOSTICS INC	570 WESTWOOD PLZ STE 6350	LOS ANGELES	CA	90095	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	1	5/10/2021	NEW	-$289,732
2021	2020	EARLYDIAGNOSTICS INC	570 WESTWOOD PLZ STE 6350	LOS ANGELES	CA	90095	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	1	6/15/2021	NEW	$289,732
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $351,646 )
2020	2020	EARLYDIAGNOSTICS INC	570 WESTWOOD PLZ STE 6350	LOS ANGELES	CA	90095	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	1	5/26/2020	NEW	$351,646
														Subtotal = $351,646

Grand Total All Awards = $351,646

Top

All Categories

About

Search

Reports

Data Submission

Award Information

An Accurate, Non-invasive, and Cost-effective Methylome Test for Early Cancer Detection

Award Number: R43CA246941

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer